Capital International Sarl Has $7.36 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital International Sarl increased its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 9.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 186,920 shares of the company's stock after buying an additional 16,397 shares during the period. Capital International Sarl owned 0.22% of CRISPR Therapeutics worth $7,357,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of CRSP. Magnetar Financial LLC acquired a new position in CRISPR Therapeutics during the 4th quarter worth $359,000. Capital Market Strategies LLC bought a new stake in CRISPR Therapeutics during the 4th quarter valued at approximately $461,000. Vanguard Group Inc. grew its holdings in CRISPR Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock valued at $68,329,000 after buying an additional 10,579 shares during the last quarter. KBC Group NV increased its position in CRISPR Therapeutics by 2,047.4% in the 4th quarter. KBC Group NV now owns 60,514 shares of the company's stock worth $2,382,000 after buying an additional 57,696 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of CRISPR Therapeutics during the fourth quarter worth approximately $3,231,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CRSP. Cantor Fitzgerald restated a "neutral" rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. StockNews.com raised CRISPR Therapeutics to a "sell" rating in a report on Friday, March 21st. Bank of America decreased their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Stifel Nicolaus cut their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a research note on Thursday, February 13th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, April 9th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of "Hold" and an average target price of $73.11.

Insiders Place Their Bets

In other news, COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now owns 8,263 shares in the company, valued at $350,516.46. The trade was a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,381 shares of company stock worth $1,608,243. Company insiders own 4.10% of the company's stock.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP traded down $0.07 on Thursday, hitting $38.47. 659,137 shares of the stock were exchanged, compared to its average volume of 1,633,713. The stock has a market capitalization of $3.32 billion, a price-to-earnings ratio of -8.80 and a beta of 1.85. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $67.88. The company's 50-day moving average price is $40.51 and its 200 day moving average price is $43.62.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.